MLTX – moonlake immunotherapeutics - class a ordinary shares (US:NASDAQ)
Stock Stats
News
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics (NASDAQ: MLTX) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Form SC 13G/A MoonLake Immunotherapeut Filed by: FMR LLC
Form 10-Q MoonLake Immunotherapeut For: Sep 30
Form 8-K MoonLake Immunotherapeut For: Nov 07
Form 4 MoonLake Immunotherapeut For: Oct 04 Filed by: BVF II GP LLC
Form SC 13D/A MoonLake Immunotherapeut Filed by: BIOTECHNOLOGY VALUE FUND L P
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.